Share

Save

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

PHASE2RECRUITING

This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.

info
Simpliy with AI

Study details:

Patients who have received CAR T-cell therapy for Relapsed/Refractory Large B-Cell Lymphoma, are in Complete Metabolic Response (CMR) or Partial Metabolic Response (PMR) and MRD positive post CAR T-cell infusion are potentially eligible. Once these patients have provided their consent, they will enter the screening phase. All events of Cytokine Release Syndrome (CRS), Haemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS), Immune-Effector Cell Associated Neurologic Syndrome (ICANS), or infection must have completely resolved.

Additionally, patients must have adequate organ and haematological function, and an ECOG performance status of up to 2. Patients deemed eligible for the study will be randomised to receive Epcor-only (Arm A) or Epcor-R2 (Arm B) for 6 cycles. The primary endpoint is CMR by Lugano 2014 criteria at month 12 post CAR T-cell infusion.

Patients will undergo an interim response assessment after 2 cycles of treatment. Patients that complete the full 6 cycles of treatment or that discontinue treatment for any reason will have an End of Treatment visit and a Safety Follow-up visit at 60 days after Day 1 of Cycle 6. Patients with non-Progressive Disease (PD) then enter the follow-up phase of the study where they will undergo response assessments at month 12, 15, 18 and 24 after CAR T-cell infusion.

Patients with PD at any time will complete a Progression visit. Patients that have completed the month 24 Follow-up visit or that they have progressed will be followed for survival and new anti-lymphoma therapy only. All patients will be followed for 2 years after the last patient randomised received the CAR T-cell infusion.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Age ≥ 18 years old at the time of signing the patient information and consent form (PICF)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • A diagnosis of relapsed/refractory large B-cell lymphoma
  • Received Therapeutic Good Administration (TGA) approved anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment.
  • Partial metabolic response (PMR) or complete metabolic response (CMR) as per the Lugano criteria on a PET/CT performed
  • MRD positive by a ctDNA assay on a blood sample post CAR T-cell infusion
  • Adequate haematological function documented within 7 days prior to randomisation
  • Adequate cardiac function.
  • Adequate renal function, documented within 7 days prior to randomisation
  • Adequate hepatic function documented within 7 days prior to randomisation
  • Complete resolution of cytokine release syndrome (CRS), macrophage-activation syndrome (MAS)/haemophagocytic lymphohistiocytosis (HLH) or immune effector cell-associated neurotoxicity syndrome (ICANS) related to prior CAR T-cell therapy.
  • Female patients of childbearing potential (FCBP) must be willing to follow the contraceptive method/procedure as outline in the PICF
  • Sexually active males must agree to use a condom during sexual contact with a pregnant female or a FCBP for the course of the study through to 4 months after the last dose of epcoritamab, even if he has undergone a successful vasectomy
  • Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction. Men must also not donate sperm during the trial and for 4 months after receiving the last dose of epcoritamab
  • The patient understands the purpose of the trial and procedures required for the trial which includes compliance with the protocol requirements and restrictions listed in the PICF and in this protocol

    • Exclusion criteria

  • A history of Grade 4 CRS or ICANS related to prior CAR T-cell therapy
  • Patients whose lymphoma is known to be CD20 negative on the most recent biopsy prior to CAR T-cell therapy
  • Ongoing active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment
  • Progression or relapse within 3 months after a regimen containing a bispecific antibody targeting CD3 and CD20
  • A diagnosis of primary central nervous system (CNS) lymphoma
  • Active secondary CNS involvement of lymphoma at time of screening
  • A known history or current autoimmune disease or other diseases resulting in permanent immunosuppression
  • Known cognitive impairment would place the patient at increased risk of complications from ICANS
  • A known history of hepatitis B serology consistent with acute or chronic infection
  • A known history of hepatitis C serology consistent with acute or chronic infection
  • A known history of testing positive for human immunodeficiency virus (HIV)
  • Any comorbidity conferring a life expectancy of < 5 years (e.g., second malignancy) or that in the opinion of the site investigator may significantly impact the ability to complete the trial therapy and follow-up or affect the interpretation of results
  • Exposed to live or live attenuated vaccine within 4 weeks prior to signing the PICF.
  • Women who are pregnant or lactating
  • Known hypersensitivity to epcoritamab, lenalidomide, rituximab, tocilizumab or their excipients
  • Presence of any psychological, social or geographical or other condition for which participation would not be in the best interest of the patient
    • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2024-05-14

    Primary completion: 2026-10-01

    Study completion finish: 2028-05-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE2

    trial

    Trial ID

    NCT06414148

    Intervention or treatment

    DRUG: Epcoritamab

    DRUG: Epcoritamab, lenalidomide and rituximab

    Conditions

    • • Relapsed/Refractory Large B-cell Lymphoma
    Image related to Relapsed/Refractory Large B-cell Lymphoma

    • Condition: Relapsed/Refractory Large B-cell Lymphoma

    • DRUG: Epcoritamab and other drugs

    • Camperdown, New South Wales, Australia and more

    • Sponsor: Peter MacCallum Cancer Centre, Australia

    You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

    Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

    Find a site

    Closest Location:

    Royal Prince Alfred Hospital

    Research sites nearby

    Select from list below to view details:

    • Royal Prince Alfred Hospital

      Camperdown, New South Wales, Australia

    • Westmead Hospital

      Westmead, New South Wales, Australia

    • Peter MacCallum Cancer Centre

      Melbourne, Victoria, Australia

    • Fiona Stanley Hospital

      Murdoch, Western Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Arm A
    • EPCORITAMAB (EPCOR-ONLY)
    DRUG: Epcoritamab
    • Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
    EXPERIMENTAL: Arm B
    • EPCORITAMAB, LENALIDOMIDE AND RITUXIMAB (EPCOR-R2)
    DRUG: Epcoritamab, lenalidomide and rituximab
    • Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.
    • Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.
    • Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    The efficacy of Epcor-only (epcoritamab alone) or Epcor-R2 (epcoritamab, lenalidomide and rituximab) consolidation as assessed by conventional (Lugano 2014) response criteria at month 12 after the CART infusionNot SpecifiedFrom start of treatment till the end of study, assessed up to approximately 12 months

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    To evaluate the safety of time-limited Epcor-only or Epcor-R2 consolidation post CAR T-cell therapy according to number of participants with treatment-related adverse events (AE) as assessed by CTCAE v5.0Not SpecifiedFrom start of treatment till the end of study, assessed up to approximately 48 months
    The efficacy as assessed by molecular and conventional response criteria at defined time points with Event Free Survival (EFS) analysesNot SpecifiedFrom start of treatment till the end of study, assessed up to approximately 48 months
    The efficacy as assessed by molecular and conventional response criteria at defined time points with Overall Survival (OS) analysesNot SpecifiedFrom start of treatment till the end of study, assessed up to approximately 48 months
    The deliverability as assessed by rates of completion of the course of therapyNot SpecifiedFrom start of treatment till the end of study, assessed up to approximately 6 months
    The deliverability as assessed by protocol-defined number of dose-reductions of lenalidomideNot SpecifiedFrom start of treatment till the end of study, assessed up to approximately 6 months

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

    Other trails to consider

    Top searched conditions

    ABN: 29 640 485 105 © 2025 Clinrol